Inactive Instrument

DIAL BIORFD Share Price Nasdaq Stockholm

DIABIO BTA

SE0019173832

Biotechnology & Medical Research

Diagonal Bio AB is a Sweden-based medical research company. The Company is developing a diagnostic platform (Panviral) for detection of any kind of pathogen. Panviralâ€™s technology is based on rapid isothermal amplification of a pathogenâ€™s genome. Multiple tests can be run in parallel, thereby increasing the sample throughput.

Employees

Sector

Biotechnology & Medical Research

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

11/12	Swedish Court Declares Diagonal Bio Bankrupt	MT
11/12	Diagonal Bio Delisted Following Bankruptcy	FW
11/12	Diagonal Bio to File for Bankruptcy in Sweden Amid 'Strained' Financials	MT
11/12	Diagonal Bio Files for Bankruptcy - Trading Halted on Shares	FW
31/25/31	Diagonal Bio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
03/25/03	Diagonal Bio Partnership to Evaluate Nasal Sampling to Detect Equine Coronavirus	MT
22/25/22	Diagonal Bio AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/25/31	Certain Shares of Diagonal Bio AB are subject to a Lock-Up Agreement Ending on 31-JUL-2025.	CI
25/25/25	Diagonal Bio Executes Directed Share Issue to TO2 Warrant Guarantors	FW
19/25/19	Diagonal Bio will receive SEK 3.6 million through the exercise of warrants.	FW
17/25/17	Diagonal Bio has made progress in developing a test for the bacteria that causes strangles.	FW
11/25/11	Diagonal Bio has converted two Lamplify pilots into instrument sales.	FW
09/25/09	Svea Bank exercises warrants in Diagonal Bio to subscribe for shares	FW

11/12	Diagonal Bio has been declared in bankruptcy	AQ
11/12	Diagonal Bio intends to submit a formal application for bankruptcy	AQ
01/12	Nomination Committee appointed for Diagonal Bio	AQ
04/11	Untersteiner Racing signs agreement for a pilot test	AQ
31/25/31	Diagonal Bio publishes interim report for the third quarter of 2025	AQ

Manager	Title	Age	Since
Karin Wehlin CEO	Chief Executive Officer	-	23/11/2023
Fata Mrsic DFI	Director of Finance/CFO	-	14/06/2024
Emelie Danefur CTO	Chief Tech/Sci/R&D Officer	-	01/01/2024

Director	Title	Age	Since
Carl Edvard Georg Hall BRD	Director/Board Member	41	01/01/2021
Kerstin Åkesson Jakobsson CHM	Chairman	70	01/01/2021
Kushagr Punyani BRD	Director/Board Member	35	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAL BIORFD	+2.99%	+15.00%	-	-	7L
LONZA GROUP AG	+0.56%	-4.71%	-2.45%	+9.18%	4.56TCr
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	4.4TCr
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	4.37TCr
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	4.02TCr
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	3.19TCr
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	1.74TCr
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	1.66TCr
EUROFINS SCIENTIFIC SE	+2.07%	+0.78%	+13.07%	+30.91%	1.45TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	1.3TCr
Average	+1.02%	-2.42%	+63.95%	+107.03%	2.97TCr
Weighted average by Cap.	+0.95%	-2.82%	+75.86%	+127.94%

DIAL BIORFD Share Price Nasdaq Stockholm

Stocks

DIABIO BTA

SE0019173832

Biotechnology & Medical Research

Latest news: DIAL BIORFD

Press Releases: DIAL BIORFD

Quotes and Performance

Managers and Directors: DIAL BIORFD

Other Biotechnology & Medical Research

Company Profile